Study #2021-1163
A Multicentre, Open-Label, Non-Randomized, Phase 1a/1b Study of NG-350A, a Tumour-Selective Anti-CD40-Expressing Adenoviral Vector, in Combination with Pembrolizumab in Patients with Metastatic or Advanced Epithelial Tumours (FORTIFY)
MD Anderson Study Status
Not Accepting
Treatment Agent
NG-350A plus Pembrolizumab
Description
This is a phase 1a/1b, multicentre, open-label, non-randomized study of NG-350A in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Epithelial Tumor, Metastatic Cancer
Study phase:
Phase I
Physician name:
Aung Naing
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-760-2503
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.